Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma

Click to increase image sizeClick to decrease image size

Acknowledgments

We would like to thank the patients and their families for their participation in this clinical study. We would like to thank Katherine Yang and Benedetto Farsaci for providing receptor occupancy data, and Payal Parikh-Patel, Mihaela Popa McKiver and Brian Lestini of Bristol-Myers Squibb for their critical review of the manuscript.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1320713.

Additional information

Funding

This work was supported in part by the Memorial Sloan Kettering Cancer Center (MSKCC) NCI core [grant P30 CA008748] (A.M.L.). M.J.P. is supported in part by the MSKCC Mortimer J. Lacher Fellowship supported by the Lymphoma Foundation and also supported in part by a grant from the NIH/National Center for Advancing Translational Sciences (UL1TR00457), administered by the Clinical and Translational Science Center at Weill Cornell Medical Center and MSKCC. A.M.L. is a member of the Parker Institute for Cancer Immunotherapy, which supported the MSKCC Cancer Immunotherapy Program. A.M.L. also receives support from the MSK Sawiris Foundation and Cycle For Survival.